![]() ![]() ![]() A multivariate analysis of prognostic factors for 8-week mortality identified the following to be independently adverse: age ≥ 80 years, complex karyotypes, (≥ 3 abnormalities), poor performance (2-4 Eastern Cooperative Oncology Group), and elevated creatinine > 1.3 mg/dL. Survival was similar among patients treated before 2000 and since 2000. The median survival was 4.6 months, and the 1-year survival rate was 28%. Excluding patients with favorable karyotypes, the overall complete response rate was 45%, 4-week mortality was 26%, and 8-week mortality was 36%. We analyzed 446 patients ≥ 70 years of age with AML (≥ 20% blasts) treated with cytarabine-based intensive chemotherapy between 19 to identify risk groups for high induction (8-week) mortality. Recent studies suggested that intensive AML-type therapy is tolerated and may benefit most. Patients ≥ 70 years of age with acute myeloid leukemia (AML) have a poor prognosis. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |